Net revenue increased 11% to a record $206.7 million in Q3 Fiscal 2026, compared to $185.8 million in the prior year. Gross profit increased 6% to a record $55.0 million in Q3 Fiscal 2026, up from $52.0 million. Net loss improved 97% to $25.2 million, significantly down from a net loss of $793.5 million in the prior year. Adjusted EBITDA increased 19% to $10.7 million in Q3 Fiscal 2026, compared to $9.0 million. International cannabis net revenue accelerated with 73% growth year-over-year, and cannabis flower sales volume increased 100%. Canadian adult-use and medical cannabis net revenue combined increased 8% year-over-year, maintaining Tilray's #1 cannabis leadership position in Canada by revenue. The acquisition of BrewDog for approximately $40 million cash positions Tilray as a global craft beverage leader with multi-region expansion. The company maintains a strong balance sheet with $265 million in cash and marketable securities and a net cash position of approximately $3.5 million. Project 420 synergy program was completed, delivering approximately $33 million in annualized cost savings for the Beverage business. Fiscal Year 2026 guidance for adjusted EBITDA of $62 million to $72 million (13% to 31% growth) was reconfirmed.